Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Novel Nasal Treatment for COVID-19
NCT05799521Phase 2Active, not recruiting
- Sponsor
- Indiana University
- Start
- Jun 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Optate in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Indiana University. Primary endpoints: SARS-CoV-2 Viral Levels at 1 hour and Sino-Nasal Outcome Test-22 at 24 hours. Started Jun 2023; status: active, not recruiting.
02
Drugs
Optate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05799521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799521.